Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Modifies Procrit Pricing Practices To Compete With Amgen’s Aranesp 

Executive Summary

Johnson & Johnson is modifying its pricing practices for Procrit (epoetin alfa) to compete with Amgen's Aranesp (darbepoetin alfa)

You may also be interested in...



J&J Draws Line On Procrit Price; Will Not Meet Amgen Aranesp 40% Discount

Johnson & Johnson will not be matching Amgen's latest discounts in the EPO market, J&J CFO Robert Darretta indicated during an April 13 investor call

J&J Draws Line On Procrit Price; Will Not Meet Amgen Aranesp 40% Discount

Johnson & Johnson will not be matching Amgen's latest discounts in the EPO market, J&J CFO Robert Darretta indicated during an April 13 investor call

J&J Procrit Pricing Practices Stabilize Sales, Position Product For Rebound

J&J pricing strategies have stabilized Procrit sales, possibly positioning the struggling franchise for a rebound, CEO William Weldon stated

Related Content

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel